Exiqon Expects Initial Data from Blood-Based Colon Cancer Dx in Early 2010

The company also reported its financial results for the first half of 2009, posting a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories